Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025     Amgen Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-37702 95-3540776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           One Amgen Center Drive   Thousand Oaks , California   91320-1799 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (805) 447-1000     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The Nasdaq Global Select Market 2.00% Senior Notes due 2026   AMGN26   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on May 23, 2025. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows: Item 1 - Election of Directors Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2026 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.   Name Votes For Votes Against Abstain Broker Non-Votes Dr. Wanda M. Austin 399,241,184 4,695,034 624,456 64,590,100 Mr. Robert A. Bradway 375,676,872 26,441,785 2,442,017 64,590,100 Dr. Michael V. Drake 399,379,212 4,268,118 913,344 64,590,100 Dr. Brian J. Druker 399,421,475 4,481,785 657,414 64,590,100 Mr. Robert A. Eckert 381,713,097 21,605,957 1,241,620 64,590,100 Mr. Greg C. Garland 384,198,583 19,699,619 662,472 64,590,100 Mr. Charles M. Holley, Jr. 396,883,070 7,000,392 677,212 64,590,100 Dr. S. Omar Ishrak 398,671,821 5,218,699 670,154 64,590,100 Dr. Tyler Jacks 392,818,616 10,591,022 1,151,036 64,590,100 Dr. Mary E. Klotman 400,133,252 3,547,127 880,295 64,590,100 Ms. Ellen J. Kullman 399,256,857 4,429,859 873,958 64,590,100 Ms. Amy E. Miles 399,556,351 4,116,751 887,572 64,590,100 Item 2 - Advisor y Vote to A pprove Our Executive Compensation The advisory vote to approve our executive compensation was approved.    For: 381,269,281  Against: 21,382,050  Abstain: 1,909,343  Broker Non-Votes: 64,590,100 Item 3 - Ratification of Selection of Inde pendent Re gistered Public Accountants Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2025. No Broker Non-Votes resulted from the vote on this proposal.    For: 441,615,581  Against: 26,675,877  Abstain: 859,316 No other matters were submitted for stockholder action. SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     AMGEN INC. Date: May 23, 2025 By: /s/ Jonathan P. Graham Name: Jonathan P. Graham Title: Executive Vice President and General Counsel and Secretary